RNAdjuvant®, a novel RNA-based immunomodulator, combines strong immunostimulatory capacities with a favourable safety profile

CureVac has developed a novel nanoparticular RNA-based adjuvant formulation with strong immunostimulatory properties. RNAdjuvant® can be combined with different antigenic formats, like recombinant proteins and peptides, resulting in dramatically increased immunogenicity of these vaccines.